#95 Landmark Clinical Evidence
Peer-reviewed human research with direct implications for cannabis medicine practice.
Two Cincinnati breweries have filed a lawsuit challenging Ohio’s prohibition on THC-infused beverages, arguing the state ban violates constitutional protections and creates an unequal regulatory landscape compared to other cannabis products. Ohio currently permits THC in edibles, tinctures, and topicals under its medical cannabis program, but explicitly excludes beverages from the approved product categories, creating a gap that the breweries contend is arbitrary and anticompetitive. The legal challenge could reshape how states classify and regulate cannabis-infused consumables, potentially affecting product availability and consistency across jurisdictions where clinicians practice. For physicians recommending cannabis products to patients, regulatory decisions like these determine which delivery methods are legally accessible and how product standardization and quality assurance are enforced in their state. The outcome may influence whether beverage formulations become an available option for patients who prefer this delivery method or have difficulty with other cannabis forms. Clinicians should monitor similar regulatory cases in their states, as the resolution could expand or restrict the product options available to their cannabis-using patients.
“What we’re seeing with these lawsuits is the predictable collision between federal prohibition and state legalization, and it’s creating a real problem for my patients who legitimately want cannabis as a beverage option rather than smoking or edibles that spike their blood levels unpredictably. Until we have federal rescheduling and clear interstate commerce rules, we’ll keep watching the market get fragmented by litigation instead of science-based regulations that actually serve public health.”
⚖️ The legal challenge to Ohio’s ban on THC-infused beverages highlights an emerging tension between state-level cannabis regulation and the commercial interests of the beverage industry, with potential implications for how clinicians counsel patients about cannabis products. As more jurisdictions legalize cannabis, the proliferation of novel delivery methods like beverages creates clinical uncertainty regarding dosing consistency, onset timing, and patient adherence patterns compared to traditional forms. Clinicians should be aware that litigation outcomes may rapidly change the legal landscape in their states, potentially expanding patient access to products with limited long-term safety data and variable quality standards. Important confounders include the lack of standardized manufacturing practices, variable THC potency within products, and the difficulty patients may have distinguishing THC beverages from regular drinks, which could increase accidental ingestion risks in households with children or cognitively impaired adults. For clinical practice, this means staying informed about evolving state regulations
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: